PMID- 11565832
OWN - NLM
STAT- MEDLINE
DCOM- 20020308
LR  - 20191105
IS  - 1524-9557 (Print)
IS  - 1524-9557 (Linking)
VI  - 24
IP  - 4
DP  - 2001 Jul-Aug
TI  - Major histocompatibility complex-restricted lysis of neuroblastoma cells by 
      autologous cytotoxic T lymphocytes.
PG  - 305-11
AB  - Vigorous host immune reactivity to neuroblastoma may correlate with better 
      prognosis, but identification of human cytotoxic T-lymphocyte (CTL) responses has 
      been relatively unsuccessful. We generated neuroblastoma-reactive CTL lines from 
      two human leukocyte antigen (HLA) A2+ neuroblastoma patients by stimulation of 
      peripheral blood lymphocytes (PBLs) with irradiated autologous tumor cells 
      pretreated with interferon-gamma in the presence of low concentrations of 
      interleukin-2 (5 U/mL). These lines lyse autologous tumor cells but do not kill 
      HLA mismatched allogeneic tumor cells, Epstein-Barr virus-transformed autologous 
      B cells, or standard natural killer cell targets. Cytotoxic T lymphocytes 
      generated from one patient recognize tumor cells from several HLA-A2 matched 
      children, although the other patient's CTLs do not kill tumor cells from other 
      HLA-A2+ individuals. Pretreatment of CTLs or target cells with appropriate 
      standard monoclonal antibodies demonstrates that these CTLs are major 
      histocompatibility complex class I (HLA-A2) restricted and that the effector cell 
      population is CD8+. Our findings suggest that these tumor cells express at least 
      one common HLA-A2 restricted antigen and at least one unique private epitope. 
      Autologous tumor-specific CTLs can be readily generated from patients' PBLs and 
      maintained in long-term culture using standard techniques.
FAU - Sarkar, A K
AU  - Sarkar AK
AD  - DeBakey Department of Surgery, Baylor College of Medicine, and The Texas 
      Children's Cancer Center, Texas Children's Hospital, Houston, USA.
FAU - Burlingame, S M
AU  - Burlingame SM
FAU - Zang, Y Q
AU  - Zang YQ
FAU - Dulai, V
AU  - Dulai V
FAU - Hicks, M J
AU  - Hicks MJ
FAU - Strother, D R
AU  - Strother DR
FAU - Nuchtern, J G
AU  - Nuchtern JG
LA  - eng
GR  - CA 78456/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Immunother
JT  - Journal of immunotherapy (Hagerstown, Md. : 1997)
JID - 9706083
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A2 Antigen)
SB  - IM
CIN - J Immunother. 2001 Jul-Aug;24(4):281-2. PMID: 11565827
MH  - Antigens, Neoplasm/immunology
MH  - Cell Line
MH  - Child
MH  - Child, Preschool
MH  - Epitopes
MH  - Female
MH  - HLA-A2 Antigen/*immunology
MH  - Humans
MH  - Infant
MH  - Male
MH  - Neuroblastoma/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
EDAT- 2001/09/22 10:00
MHDA- 2002/03/09 10:01
CRDT- 2001/09/22 10:00
PHST- 2001/09/22 10:00 [pubmed]
PHST- 2002/03/09 10:01 [medline]
PHST- 2001/09/22 10:00 [entrez]
AID - 10.1097/00002371-200107000-00006 [doi]
PST - ppublish
SO  - J Immunother. 2001 Jul-Aug;24(4):305-11. doi: 10.1097/00002371-200107000-00006.